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ABSTRACT
Introduction: Pulmonary aspergillosis has variable
course of illness, severity and outcomes depending on
underlying conditions. There is limited data available
on the clinical manifestations and outcome of
pulmonary aspergillosis from Pakistan.
Methods: To determine the clinical manifestations and
outcome of pulmonary aspergillosis in a tertiary care
hospital a retrospective study was conducted from
2004 to 2014 in patients admitted with pulmonary
aspergillosis at the Aga Khan University Hospital
Karachi, Pakistan.
Results: Of the 280 cases with provisional diagnosis
of aspergillosis 69 met the inclusion criteria. The mean
age was 45±15.7 years, 48 (69.6%) were men and 21
(30.4%) had diabetes mellitus (DM). The average
length of hospital stay (LOS) was 10.61±9.08 days.
Aspergillus fumigatus was the most common (42.0%),
followed by Aspergillus flavus (28.9%). More than one-
third of patients previously had tuberculosis (TB)
(39.13%). The commonest pulmonary manifestation
was chronic pulmonary aspergillosis (CPA) 47 (68.1%)
followed by invasive pulmonary aspergillosis (IPA) 12
(17.4%) and subacute invasive aspergillosis (SAIA) 8
(11.6%). Surgical excision was performed in 28
patients (40.57%). Intensive care unit admission was
required for 18 patients (26.08%). Case fatality rate
was 14/69 (20.3%). DM, mean LOS and hypoxic
respiratory failure were identified as independent risk
factors of mortality on multivariate analysis.
Conclusion: A. fumigatus was the most frequent
species found especially in patients with prior TB. CPA
was the commonest pulmonary manifestation seen as
post TB sequel. Diabetes, hypoxic respiratory failure
and increased LOS were independent predictors of
poor outcomes. Overall patients had good outcome
with CPA compared with SAIA and IPA.
INTRODUCTION
Aspergillosis is a spectrum of diseases cause
by the Aspergillus spp. that are ubiquitous
saprophytic fungi. The clinical spectrum of
aspergillosis varies from the colonisation of
the organism to the presence of fungus ball
(aspergilloma) or an allergic response known
as allergic bronchopulmonary aspergillosis
(ABPA) to subacute invasive aspergillosis
(SAIA) or as chronic necrotising pneumonia
and invasive pulmonary aspergillosis (IPA).1
Aspergillus fumigatus has been reported to be
responsible for more than 90% cases of inva-
sive aspergillosis.2 Aspergillus ﬂavus, Aspergillus
terreus, and Aspergillus niger are responsible for
the remaining invasive cases. The incidence
of IPA globally is increasing due to increase
in immunosuppressed patients but its
true incidence is unclear in Pakistan.
Aspergilloma is usually found in patients with
previously formed lung cavities, whereas
ABPA is a hypersensitivity reaction to
Aspergillus antigens, and is usually seen in
patients with atopy, asthma or cystic ﬁbrosis.3
Pulmonary aspergillosis has a variable course
of illness, severity and outcomes.
According to the WHO report in 2011,
around 1.2 million people in the world have
been estimated to have chronic pulmonary
aspergillosis (CPA) as a sequel to tuberculosis
(TB) and most cases occur in South-East
Asia, Western Paciﬁc and African regions.4
Scarce data is available on CPA as a post-TB
sequel and in structural lung diseases from
developing countries.
The aim of this study is to determine the
clinical manifestations and outcomes of
KEY MESSAGES
▸ Pulmonary aspergillosis has variable clinical pre-
sentations and outcomes.
▸ Very limited data is available from Pakistan on
its different clinical presentations.
▸ Chronic pulmonary aspergillosis (CPA) is the
commonest pulmonary manifestation as post-TB
sequel.
▸ Overall patients had good outcome with CPA
compared with subacute invasive pulmonary
aspergillosis (SAIA) and invasive pulmonary
aspergillosis (IPA).
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pulmonary aspergillosis in a tertiary care hospital in
Karachi, Pakistan to help understand the nature of
disease and to improve the clinical outcome in this part
of the world.
METHODS
This is a retrospective study in patients admitted with
pulmonary aspergillosis at the Aga Khan University
Hospital (AKUH), Karachi, Pakistan from January 2004
to December 2014. The research protocol of this study
was approved by the Ethical Review Committee of the
Aga Khan University. All patients admitted with a diag-
nosis of aspergillosis using International Classiﬁcation of
Disease, Ninth Revision codes (ICD-9 1173) were identi-
ﬁed. Information was collected from Health Information
Management Services (HIMS), Department of AKUH.
Data on demographics, comorbid, underlying lung con-
dition, radiographic and microbiological ﬁndings, mean
length of hospital stay (LOS), requirement of invasive
and non-invasive mechanical ventilation (NIMV),
respiratory complications and in hospital mortality was
collected on a predesigned form.
Inclusion criteria were (1) patient 18 years and above.
(2) Positive sputum and/or positive bronchoalveolar
lavage (BAL) (smear and/or culture) for Aspergillus
and/or positive lung histopathology suggestive of asper-
gillosis. (3) Chest X-ray/CT scan of the chest inﬁltrates
suggestive of aspergillosis. We excluded all patients with
culture positive for Aspergillus other than respiratory spe-
cimen, and whose medical records are with incomplete
information. Culture positive cases suggestive of colon-
isation only were also excluded. Outcomes were
in-hospital mortality, mean LOS and respiratory
complications.
Patients were classiﬁed further into CPA, SAIA, IPA
and ABPA. CPA was deﬁned as one or more cavities with
or without a fungal ball or nodules on thoracic imaging,
direct evidence of Aspergillus infection (microscopy or
culture from biopsy) or an immunological response to
Aspergillus spp. and exclusion of alternative diagnoses, all
present for at least 3 months.5 CPA was further classiﬁed
into two categories (1) single cavity with single fungal
ball with no radiological progression over at least
3 months of observation is labelled as single (simple)
pulmonary aspergilloma and (2) patients with one or
more pulmonary cavities containing one or more asper-
gilloma with serological or microbiological evidence of
Aspergillus spp. and signiﬁcant pulmonary and/or sys-
temic symptoms and evidence of radiographic progres-
sion (new cavities and increasing inﬁltrates) over at least
3 months of observation were labelled as chronic cavi-
tary pulmonary aspergillosis (CCPA).
SAIA deﬁned as invasive aspergillosis with mildly
immunocompromised host occurred over 1–3 months
with variable radiographic features and biopsy showed
hyphae in invading lung tissue.5 Patients with histology
and/or culture of a specimen of tissue taken from a site
of disease showed evidence of Aspergillus was labelled as
proven IPA. While the probable and possible invasive
infections were determined by a host factor, clinical
signs and symptoms, and mycological evidence that
encompassed culture and microscopic analysis.6 Patients
were labelled ABPA depending on the criteria as
reported previously by Rosenberg et al.7
Laboratory methods
Fungal cultures were performed at the Aga Khan
University Clinical Laboratory, which is one of the
largest laboratories in Pakistan. This laboratory is a
regional supranational laboratory for TB and regularly
participates in College of American Pathologists (CAP)
surveys for Mycology smear and culture. During the
study period fungal smear was made using 10% potas-
sium hydroxide (KOH). Sputum and tracheal aspirates
for fungal culture were processed semiquantitatively by
picking up the most purulent portion and BAL were
centrifuged at 1200×g for 10 min and the sediment was
used for microscopy and culture inoculation. The spe-
cimen was inoculated on two plates of Sabouraud
Dextrose Agar (incubated at 28°C and 37°C), one
plate of Sheep Blood Agar (incubated at 37°C), one
plate of Potato Dextrose Agar (incubated at 28°C) and
one plate of Mycosel Agar containing cycloheximide
(incubated at 28°C). All plates were reviewed by
trained laboratory technologist and consultant micro-
biologist daily for ﬁrst week and then twice weekly for
3 weeks.
Culture plates were incubated and examined until
4 weeks before reporting them as negative. Any fungal
growth was assessed by clinical microbiologist for clinical
signiﬁcance and to rule out contamination and only sig-
niﬁcant isolates were further processed and identiﬁed.
Identiﬁcation of Aspergillus spp. was made on the basis
of gross appearance and microscopic morphology of the
colonies.8
Statistical analysis
All analyses were conducted by using the SPSS (Release
19.0, standard version, copyright © SPSS; 1989–2002). A
descriptive analysis was performed for demographic fea-
tures presented as mean±SD for quantitative variable
that is, age and lengths of hospital stay. Number (per-
centage) for qualitative variables that is, gender, mortal-
ity, smokers, associated underlying disease, presenting
symptoms, radiographic ﬁndings, isolated Aspergillus
spp., and respiratory complications associated with
Aspergillus. Comparisons were made between the alive
and dead patients and χ2 test of independence was
carried out. Multivariate logistic regression analysis
was performed on variables reaching signiﬁcance on
univariate analysis to determine factors predicting the
poor outcome. All p value ≤0.05 was taken as
signiﬁcant.
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RESULTS
A total of 280 cases were reviewed with aspergillosis from
January 2004 to December 2014 and 69 met the inclu-
sion criteria. These cases were further classiﬁed as: CPA
47 cases (68.1%) including aspergilloma 26 cases
(55.3%) and CCPA 21 cases (44.7%). IPA was found in
12 cases (17.4%), which included 2 (16.7%) proven and
10 (83.37%) probable cases. ABPA was found in two
cases (2.9%) and SAIA was found in eight cases (11.6%)
of which six patients (75%) had diabetes and two
patients (25%) had active TB with underlying chronic
obstructive pulmonary disease (COPD) (ﬁgure 1).
The mean age was 45±15.7 years, 48 patients (69.6%)
were men and 43 (62.3%) were non-smokers. The most
common associated systemic illness was diabetes mellitus
(DM) n=21 (30.4%) followed by chronic renal failure
n=16 (23.2%) and haematological malignancies n=10
(14.5%). It was noted that 21.8% patients were on sys-
temic corticosteroids, 8.7% were neutropaenic and
7.24% were on chemotherapy. The commonest asso-
ciated underlying lung disease was TB n=36 (52.2%), of
which 39.1% had history of TB and 13.04% had active
TB (table 1).
Symptoms were usually non-speciﬁc, commonest symp-
toms being cough (n=44, 63.76%), followed by fever
(n=40, 57.9%), haemoptysis (n=40, 57.9%) and weight
loss (n=20, 28.9%).
On chest imaging, 29 patients (42.0%) had nodular
inﬁltrates, 25 (36.23%) had fungal ball, 24 (34.8%) had
cavitary lesions, 19 (27.58%) had consolidation, 14
(20.3%) had ﬁbrosis/pleural thickening and 10 (14.5%)
had bronchiectasis.
Sputum/BAL culture was positive for Aspergillus spp.
in 46 (66.7%) patients, 31 (44.9%) had positive histo-
pathology, 38 (55.1%) had positive culture only, 23
(33.3%) had only histopathology while both were posi-
tive in 8 (11.6%) patients. The most commonly isolated
species was A. fumigatus n=29 (42.0%) followed by A.
ﬂavus n=20 (28.9%), A. niger n=7 (10.1%) and A. terreus
n=5 (7.2%), 33 (47.8%) patients had single Aspergillus
spp., while 13 (18.8%) patients had two or more
Aspergillus spp. in culture, while in 23 (33.3%) only
fungal smear was positive.
Respiratory complications developed in 28 (40.6%)
patients. Hypoxic respiratory failure was the commonest
complication in these patients followed by pneumo-
thorax (table 2).
The mean LOS was 10.61±9.08 days. Intensive care
unit (ICU) admission was required in 18 patients
Figure 1 Showing enrolment of patients with pulmonary aspergillosis.
Table 1 Characteristics of patients with pulmonary
aspergillosis
Patient characteristics Total n=69%
Age (mean) years 45±15.7
Male 48 (69.6%)
Female 21 (30.4%)
Smoking status
Non-smokers 43 (62.3%)
Current smokers 2 (2.9%)
Ex-smoker 19 (27.5%)
Associated risk factors
Diabetes mellitus 21 (30.4%)
Chronic renal failure 16 (23.2%)
Haematological malignancies 10 (14.5%)
CLD 3 (4.3%)
Steroids use 15 (21.8%)
Neutropaenia 6 (8.7%)
Chemotherapy 5 (7.24%)
Associated lung disease
Previous TB 27 (39.1%)
Active TB 9 (13.04%)
Bronchiectasis 10 (14.5%)
COPD 7 (10.14%)
Asthma 7 (10.14%)
ILD 3 (4.34%)
CLD, chronic liver disease; COPD, chronic obstructive pulmonary
disease; ILD, interstitial lung disease; TB, tuberculosis.
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(26.1%) and mechanical ventilation in 17 (24.61%).
NIMV used in eight (11.6%) patients.
Mortality was seen in 14 patients (20.3%) and was
higher in ICU patients (n=13/18, 72.2%) and in IPA
7/12 (58.3%), SAIA 4/8 (50%) compared with CPA
3/47 (6.4%).
Factors associated with mortality
On univariate analysis (table 3), DM was a signiﬁcant
comorbidity (p value 0.05), followed by haematological
malignancy (p value 0.01) and renal failure (p value
0.002). The non-survivors had a longer ICU stay (p
value 0.001), more respiratory complications (p value
0.002) and greater mean LOS (p value 0.009) compared
with survivors. Patients with consolidation had higher
mortality (p value 0.001). Patients with fungal ball who
Table 2 Clinical outcomes in patients with pulmonary
aspergillosis
Clinical outcomes Number n (%)
Respiratory complications n=28 (40.6%)
Hypoxic respiratory failure 23 (33.3%)
Pneumothorax 10 (14.5%)
Massive haemoptysis 1 (1.4%)
Bronchopleural fistula 2 (2.89%)
Empyema/lung abscess 2 (2.89%)
Length of hospital stay (mean) days 10.61±9.08
ICU admission 18 (26.08%)
Intubation and mechanical ventilation 17 (24.63%)
NIMV 8 (11.59%)
Overall mortality 14 (20.3%)
Mortality in ICU 13 (72.22%)
ICU, intensive care unit; NIMV, non-invasive mechanical
ventilation.
Table 3 Risk factors associated with mortality in patients with pulmonary aspergillosis
Dead, n=14 Alive, n=55 p Value
Age (years)
<35 2 (14.3) 18 (32.7) 0.31
35–45 3 (21.4) 13 (23.6)
>45 9 (64.3) 24 (43.6)
Gender
Male 8 (57.1) 40 (72.7) 0.25
Female 6 (42.9) 15 (27.3)
Smoking status
Current 2 (16.7) 0 0.004
Ex-smoker 1 (8.3) 18 (34.6)
Non-smoker 9 (75) 34 (65.4)
Renal failure 8 (57.14) 8 (14.54) 0.002
DM 8 (57.1) 14 (25.5) 0.05
Steroids use 3 (21.4) 12 (21.8) 0.64
Chemotherapy 2 (14.28) 3 (5.4) 0.26
Haematological malignancies 5 (35.7) 5 (9.1) 0.01
Past TB 2 (14.2) 25 (45.45) 0.22
Active TB 2 (14.2) 7 (12.7) 0.58
COPD 0 7 (12.7) 0.18
Asthma 2 (14.28) 5 (9.09) 0.43
Nodular infiltrates 9 (64.28) 20 (36.36) 0.29
Consolidation 11 (78.57) 8 (14.54) 0.001
Bronchiectasis 1 (7.14) 9 (16.36) 0.24
Fungal ball 3 (21.4) 22 (40.0) 0.11
Respiratory complications 11 (78.6) 17 (30.9) 0.002
Length of hospital stay (mean days) 16.2±10.4 9.1±8.2 0.009
Pneumothorax 3 (21.4%) 7 (12.72%) 0.32
ICU stay 13 (92.85%) 5 (9.09%) 0.001
Mechanical ventilation 14 (100%) 3 (5.45%) 0.001
NIMV use 1 (7.14%) 7 (12.72%) 0.48
Surgical resection 1 (7.1) 27 (49.1) 0.001
Independent factors associated with mortality on multivariate analysis
Factors OR ( 95% CI) p Value
Hypoxic respiratory failure 6.80 (1.46 to 31.60) 0.01
DM 6.91 (1.46 to 32.54) 0.01
Length of hospital stay (mean days) 1.08 (1.007 to 1.15) 0.03
DM, diabetes mellitus; ICU, intensive care unit; NIMV, non-invasive mechanical ventilation; TB, tuberculosis.
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underwent surgical excision had good outcomes (p
value 0.001).
DM, mean LOS and hypoxic respiratory failure were
identiﬁed as independent risk factors of mortality on
multivariate analysis (table 3).
DISCUSSION
This is the ﬁrst study describing clinical features and
outcome of pulmonary aspergillosis from a tertiary care
hospital from Pakistan. The prevalence of fungal infec-
tion has dramatically increased over recent years due to
underlying risk factors.9 Culture remains a gold standard
for the diagnosis of aspergillosis but has low sensitivity.
Culture positivity does not always reﬂect infection as
these organisms could also occur as colonisers or con-
taminants. We have reported a higher culture positivity
rate (66.7%) of sputum/BAL compared with 23.3%
from an Indian study.10 This high positivity rate could
also reﬂect colonisation or contamination; however in
these cases growth of Aspergillus spp. was reported only
after assessing signiﬁcance. In addition, the laboratory
strictly monitors culture contamination rate as a quality
indicator, also all specimens were processed in safety
cabinet to avoid contamination within laboratory during
processing. Furthermore clinical evaluation of these
cases also conﬁrmed the signiﬁcance of the growth.
Recent advances of diagnosis of invasive aspergillosis
include antigen detection tests; galactomannan and
β-D-glucan (component of cellular wall). Both these
tests are approved by the US Food and Drug
Administration (FDA) for the diagnosis of IPA. They
help in the early diagnosis and conﬁrmation of IPA and
are also helpful in the assessment of the evolution of
infection during treatment with serial levels.11
Unfortunately, the antigen detection tests were not avail-
able at our centre during the study period and the rates
of aspergillosis reported could be an underestimate.
Majority of patients in this study were men and the
commonest isolated species was A. fumigatus similar to
the previous literature2 10 followed by A. ﬂavus, A. niger
and A. terreus. We found CPA as the most common pul-
monary manifestation. In the literature the commonest
form of CPA is CCPA.5 However, the incidence of asper-
gilloma was more common than CCPA in our study; this
may be because ours is a tertiary care hospital and
patients are referred for interventions. Patients with pul-
monary insults like COPD, chronic ﬁbrocystic healed
TB, interstitial lung disease (ILD), pneumoconiosis and
cystic ﬁbrosis are well-known risk factors for CPA.12 In
our study majority of patients had a history of TB as
reported previously.4 10 13 14 One of the reason being
that TB is endemic in Pakistan and majority of these
patients developed CPA as a post-TB sequel. It is interest-
ing to note that some of the patients also had active TB
along with Aspergillus infection; the association of active
TB with Aspergillus infection is rarely seen and reported
only in few case reports.15 16
The commonest underlying systemic condition
among our patients was DM; increased incidence of TB
among patients with diabetes is well known due to
impaired immunity and associated with aggressive
course and outcomes.17 18 Previous literature has
reported that patients with DM with TB had more
severe clinical manifestation (cavitation), severe treat-
ment and post treatment outcomes like failure and
death, death and relapse.19 20 The majority of patients
with SAIA also had underlying diabetes. So diabetes was
identiﬁed as an important risk factor for pulmonary
aspergillosis for SAIA and CPA.
DM has been rarely associated with IPA and reported
only in few case reports.21 22 In our study the majority of
cases had probable IPA but the revised deﬁnition of IPA
has some limitations as it only included immunocom-
promised patients.6 A study in 172 critically ill patients
showed that 83 had invasive disease while 60% had no
risk factors for IPA.23 Critically ill patients are prone to
develop disturbances in immunoregulation, which
makes them vulnerable for fungal infections. Thus
besides neutropaenia, haematopoietic stem cell trans-
plant, DM, renal failure, COPD, liver failure are import-
ant risk factors in ICU.
Patients with aspergillosis usually presents with non-
speciﬁc constitutional symptoms such as fever, cough,
haemoptysis and weight loss or rarely may be asymptom-
atic in CPA.24 In this study patients mostly had non-
speciﬁc symptoms. Radiographic presentation is also
variable from rounded densities, pleural-based inﬁltrates
to cavitation while pleural effusion is rarely seen.
Greene25 found 94% of patients with IPA had at least
one nodular lesion. In a study IPA in patients with neu-
tropaenia who underwent stem cell transplantation had
nodules 67%, ground glass 56% and consolidation
44%,26 while halo sign and air crescent sign were usually
non-speciﬁc.27 In CPA, patients had pleural thickening
and cavitation while fungal ball (mycetoma) can be seen
in 50%.28 In our study majority of the patients had
nodular inﬁltrates 42.2%, followed by fungal ball (myce-
toma), cavitation and consolidation.
Overall mortality was 72.2% and was higher in IPA
and SAIA compared with CPA. Mortality in CPA ranges
from 10% to 30%, low in simple aspergilloma compared
with CCPA.4 However, severity of the underlying pul-
monary disease and the extent of lung destruction are
important predictors of mortality and outcomes among
patients with CPA. Limited data is available for SAIA
while in IPA reported morality ranged from 50% to
80%.29 30 Majority of these patients developed hypoxic
respiratory failure and had bilateral consolidations.
Hypoxic respiratory failure is well known in patients with
neutropaenia during the recovery phase with IPA, likely
secondary to neutrophil inﬂux.31 32 Interestingly, in our
study only 8.69% patients were neutropaenic. This is
most likely due to low feasibility of performing invasive
procedures to collect appropriate samples for culture
and the absence of antigen detection tests during the
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study period at our institute. Besides respiratory failure
14.5% developed pneumothorax. Empyema was a rare
complication33 seen in 2.89% patients in this study.
The mean LOS is variable in patients with pulmonary
aspergillosis and available data is also limited. As in our
study population majority of the patients had CPA,
therefore it is difﬁcult to compare the results with the
available data which is particularly on IPA.
Our study has added important information on pul-
monary aspergillosis particularly from Pakistan but there
are certain limitations of this study. (1) It is a retrospect-
ive study and we cannot standardise the diagnostic and
treatment approaches in these patients. (2) It is a single
centre study and study results cannot be generalised.
(3) Galactomannan and β-D-glucan assays were not
available during this study period and could not be used
to diagnose patients in whom invasive sampling could
not be performed. We recommend large multicentre
prospective studies using β-D-glucan and galactomannan
as an adjunctive diagnostic aid as both are now incorpo-
rated in the revised European Organisation for Research
and Treatment of Cancer/Invasive Fungal Infections
Cooperative Group and the National Institute of Allergy
and Infectious Diseases Mycoses Study Group (EORTC/
MSG) criteria for diagnosing IPA6 and recommended
for CPA in BAL by European Society for Clinical
Microbiology and Infectious Diseases and European
Respiratory Society (ESCMID/ERS).5
CONCLUSION
A. fumigatus was the most frequently isolated species in
our region, found especially in patients with history of
TB. CPA was the commonest pulmonary manifestation
as post-TB sequel. Patients with diabetes, hypoxic
respiratory failure and increased LOS were independent
predictors of poor outcomes. Overall patients had good
outcome with CPA compared with SAIA and IPA.
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